BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 28343309)

  • 1. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among
    Faermann R; Friedman E; Kaidar-Person O; Weidenfeld J; Brodsky M; Shalmon A; Halshtok Neiman O; Gotlieb M; Yagil Y; Samoocha D; Madorsky Feldman D; Sklair-Levy M
    Breast J; 2022; 2022():4317693. PubMed ID: 36349178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
    Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
    Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
    van der Groep P; van Diest PJ; Smolders YH; Ausems MG; van der Luijt RB; Menko FH; Bart J; de Vries EG; van der Wall E
    PLoS One; 2013; 8(2):e56055. PubMed ID: 23409121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
    Tilanus-Linthorst M; Verhoog L; Obdeijn IM; Bartels K; Menke-Pluymers M; Eggermont A; Klijn J; Meijers-Heijboer H; van der Kwast T; Brekelmans C
    Int J Cancer; 2002 Nov; 102(1):91-5. PubMed ID: 12353239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
    Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
    Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
    J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
    Murakami W; Tozaki M; Nakamura S; Ide Y; Inuzuka M; Hirota Y; Murakami K; Takahama N; Ohgiya Y; Gokan T
    Breast Cancer; 2019 Sep; 26(5):552-561. PubMed ID: 30820924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
    Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
    Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS.
    Saito M; Matsuzaki M; Sakuma T; Katagata N; Watanabe F; Yamaguchi Y; Schetter AJ; Takenoshita S; Nomizu T
    Breast Cancer; 2014 Mar; 21(2):140-5. PubMed ID: 22875640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition.
    Obdeijn IM; Loo CE; Rijnsburger AJ; Wasser MN; Bergers E; Kok T; Klijn JG; Boetes C
    Breast Cancer Res Treat; 2010 Jan; 119(2):399-407. PubMed ID: 19876732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
    Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
    Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
    Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
    Ha SM; Chae EY; Cha JH; Kim HH; Shin HJ; Choi WJ
    AJR Am J Roentgenol; 2017 Oct; 209(4):920-928. PubMed ID: 28796549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.